Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and ...

Johnson & Johnson (NYSE: JNJ) delivered a solid earnings report on April 15. [content-module:CompanyOverview|NYSE:JNJ] On the ...

During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in ...

LD 219 threatens to limit access to harm reduction services — a range of public health efforts focused on prevention, risk reduction and health promotion — by requiring syringe service ...

JPMorgan notes that Argenx (ARGX) announced that the FDA had approved Vyvgart Hytrulo as a Pre-Filled Syringe for self-administration and ...

No significant differences in the risk of myocardial infarction, ischemic stroke, or cardiovascular-related death were observed in patients with psoriasis or psoriatic arthritis initiating treatment ...

Shields is referring to the large PBMs’ efforts to develop private-label biosimilars that compete directly with pharmaceutical companies’ biosimilars for Humira (adalimumab) and Stelara (ustekinumab).

Phil Brooks, a Black American, patented a disposable syringe design on April 9, 1974, contributing to safer healthcare. While not the inventor of the hypodermic syringe, his work added to the history ...

Biological medicines, including biosimilar medicines, play an important role in healthcare, opening up many possibilities for the treatment of disease and illness. 8 of the top 10 medicines prescribed ...

The concerns around the Stelara exclusivity appear overblown. China’s new tariffs just reignited the same market patterns that led to triple- and quadruple-digit wins for Matt Maley. Get the ...